Alkem Laboratories Limited
Alkem Laboratories received an income tax order from the Deputy Commissioner of Income Tax, Central Circle 8(1), Mumbai, disputing a tax amount of ₹333.38 crores for Assessment Year 2023-24. The company asserts no material financial impact due to available MAT credit and plans to appeal the order, believing it has strong grounds to substantiate its position.
Apr 24 2026 16:04:00
Alkem Laboratories Limited
Alkem Laboratories' CEO & KMP, Dr. Vikas Gupta, has resigned. He will serve until June 30, 2026, to facilitate a smooth transition of responsibilities.
Apr 24 2026 15:04:00
Alkem Laboratories shares crater after CEO Vikas Gupta resigns to pursue new opportunities
Vikas Gupta, CEO of Alkem Laboratories, has resigned from his position to pursue new opportunities, leading to a decline of over 4% in the company's share price in early trade. The company has initiated a handover process for succession.
Apr 24 2026 14:04:00
Alkem Laboratories Limited
Alkem Laboratories incorporated Alkem Pharma Trading FZCO, a wholly-owned subsidiary, in UAE on March 27, 2026. This move aims to strengthen the company's export presence in African, Southeast Asian, and non-UAE markets.
Apr 13 2026 15:04:00
Alkem Laboratories Ltd - 539523 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015- Incorporation Of Wholly Owned Subsidiary Of The Company
Alkem Laboratories incorporated its wholly owned subsidiary, Alkem Pharma Trading FZCO, in Dubai, UAE. This new entity, with a capital of AED 36,70,000, will focus on exporting the company’s pharmaceutical products to African, South East Asian, and non-UAE markets.
Apr 13 2026 15:04:00
Alkem Laboratories Limited
Alkem Laboratories incorporated a wholly-owned subsidiary, Alkem Pharma Trading FZCO, in Dubai, UAE. This new entity, with a subscribed capital of AED 3,670,000, aims to export the company's products to African, South East Asian, and non-UAE markets.
Apr 13 2026 15:04:00
Alkem Laboratories Limited
Alkem Laboratories submitted revised XBRL financial results for Q4 FY25, correcting discrepancies in the initial audited submission. The revised submission includes both standalone and cons. figures for the quarter ended March 31, 2025.
Apr 10 2026 18:04:00
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Alkem Laboratories launched 'A to Z Daily,' an everyday multivitamin supplement for adults. This FSSAI-approved product contains 26 essential vitamins, minerals, and botanicals for holistic nutritional support.
Apr 07 2026 15:04:00
Alkem Laboratories Limited
Alkem Laboratories launched A to Z Daily, an everyday multivitamin supplement for adults. The product is formulated with 26 essential vitamins, minerals, and botanicals, providing 100% RDA of 19 vitamins and minerals for holistic nutritional support.
Apr 07 2026 15:04:00
Alkem Laboratories Ltd - 539523 - Please Find Attached Herewith Intimation About Increase In Investment To Be Made For Setting Up Of Manufacturing Facility Of The Company In Ujjain, Madhya Pradesh.
Alkem Laboratories' board approved increasing investment for its Ujjain manufacturing facility to ₹1036 crores, up from the previously approved ₹533 crores. This strategic expansion will establish a new greenfield formulations plant in Madhya Pradesh, executed in a phased manner.
Apr 02 2026 13:04:00
Read More